Nektar Therapeutics Shares Surge on Positive Phase 2b Alopecia Trial Results

Nektar Therapeutics saw its stock price climb over 18% following successful clinical data for its hair-loss treatment. The company now plans to advance the drug candidate, rezpegaldesleukin, into later-stage trials.

• NKTR shares increased by more than 18% in a single session
• Phase 2b trial for rezpegaldesleukin showed positive hair regrowth in severe alopecia patients
• The 52-week study corrected previous failures caused by enrollment errors
• The drug candidate will now move into later-stage clinical trials
• The treatment targets a common autoimmune disorder affecting millions in the U.S.